Levisky JA, Karch SB, Bowerman DL, et al
This is why many experts now view GLP-1 drugs as chronic medications like statins or blood pressure drugs rather than short courses
In head-to-head trials, tirzepatide's dual-receptor mechanism (GLP-1 plus GIP) tended to produce larger average weight loss than semaglutide, which targets GLP-1 alone
other poor prognostic features Very high troponin level is a marker of high risk
Cardiometabolic markers including HbA1c, fasting glucose, blood pressure, cholesterol and triglycerides improved during treatment but are estimated to return to baseline levels within approximately 1.4 years after medicines stopped
And 43 percent of study participants saw an improvement in fibrosis